Back to discover
Disease
Pregnancy in Obesity
Late-stage therapeutic developmentEmerging research
2
Publications
24
Clinical trials
2025
Latest publication
Latest activity
betaRecent clinical, regulatory, research and industry developments relating to this disease.
Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment.
Research2025-09-24Best practice & research. Clinical endocrinology & metabolism
What's happening now
An analyst briefing on current research, clinical, regulatory and industry activity surrounding this disease.
Executive briefingUpdating summary…Momentum: High
Key developments
- 5 clinical trials expected to report results, the earliest in Q2 2027.
- Active recent publication activity.
Upcoming Milestones
- Q2 2027Efficacy, Metabolic and Cardiovascular Effects of Liraglutide in Children Aged 6-12 Years With Severe Obesity: A Randomized Controlled Trial With Advanced Echocardiographic Assessment
- Q3 2027A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)
- Q4 2027Effect of Metformin ER With Hypocaloric Diet on Weight Loss in Overweight/Obese Patients With Increased Waist Circumference
- Q4 2028Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c.2.4 mg Once-weekly
- Q1 2029A Phase IV Study to Assess the Effect of Naltrexone Hydrochloride Extended Release (ER) and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on the Occurrence of Major Adverse Cardiovascular Events
Major developments
Upcoming trial readoutHigh impact
Results expected Q4 20272026-06-08
Upcoming trial readoutHigh impact
Results expected Q4 20282026-06-02
Research HighlightsViewHide
- 2025-09-24Preconception use of GLP-1 and GLP-1/GIP receptor agonists for obesity treatment.Koceva A · 2025
Clinical MilestonesView all 18Hide
Results expected
- 2026-06-08Effect of Metformin ER With Hypocaloric Diet on Weight Loss in Overweight/Obese Patients With Increased Waist CircumferenceResults expected Q4 2027
- 2026-06-02Weight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c.2.4 mg Once-weeklyResults expected Q4 2028
- 2026-05-29A Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)Results expected Q3 2027
- 2026-05-15Efficacy, Metabolic and Cardiovascular Effects of Liraglutide in Children Aged 6-12 Years With Severe Obesity: A Randomized Controlled Trial With Advanced Echocardiographic AssessmentResults expected Q2 2027
- 2026-03-31A Phase IV Study to Assess the Effect of Naltrexone Hydrochloride Extended Release (ER) and Bupropion Hydrochloride ER Combination (Contrave®/Mysimba®) on the Occurrence of Major Adverse Cardiovascular EventsResults expected Q1 2029
Recently completed
- 2026-06-02Efficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (SURMOUNT-ADOLESCENTS)Primary completion
- 2026-06-01Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)Completed
- 2026-04-30A Master Protocol to Investigate the Efficacy and Safety of LY3437943 Once Weekly in Participants Without Type 2 Diabetes Who Have Obesity or Overweight: A Randomized, Double-Blind, Placebo-Controlled Trial (TRIUMPH-1)Completed
- 2026-04-23Efficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Active Psoriatic Arthritis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsA)Completed
- 2026-04-22Efficacy and Safety of Cagrilintide s.c. in Combination With Semaglutide s.c.(CagriSema s.c. 1.0 mg/1.0 mg and 1.7 mg/1.7 mg) Once-weekly in Participants With Overweight or ObesityCompleted
Other updates
- 2028-06-01Improving Access to Anti-Obesity Pharmacotherapy for Pediatric Obesity: A Randomized Placebo-Controlled Trial of PhentermineWithdrawn
- 2028-03-01A Phase 3, Randomized, Double-blind, Double-dummy, Parallel-group, Active Drug and Placebo-controlled, Safety, Efficacy and Superiority of Sibutramine IR/Topiramate XR in Overweight Adults With Comorbidities/ObesityWithdrawn
- 2028-01-17A Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or ObesityWithdrawn
- 2027-11-01Parent Toddler Obesity Study (PTOS)Withdrawn
- 2026-11-30Megestrol Acetate Versus Liraglutide Plus Megestrol Acetate in Obese Women with Endometrial Atypical Hyperplasia: a Randomized Controlled Pilot Clinical StudyWithdrawn
+10 more in the activity timeline below
Activity timeline19
- 2028-06-01ClinicalImproving Access to Anti-Obesity Pharmacotherapy for Pediatric Obesity: A Randomized Placebo-Controlled Trial of PhentermineWithdrawn
- 2028-03-01ClinicalA Phase 3, Randomized, Double-blind, Double-dummy, Parallel-group, Active Drug and Placebo-controlled, Safety, Efficacy and Superiority of Sibutramine IR/Topiramate XR in Overweight Adults With Comorbidities/ObesityWithdrawn
- 2028-01-17ClinicalA Placebo-controlled Comparability Study to Compare Two Presentations of CagriSema in Participants With Overweight or ObesityWithdrawn
- 2027-11-01ClinicalParent Toddler Obesity Study (PTOS)Withdrawn
- 2026-11-30ClinicalMegestrol Acetate Versus Liraglutide Plus Megestrol Acetate in Obese Women with Endometrial Atypical Hyperplasia: a Randomized Controlled Pilot Clinical StudyWithdrawn
- 2026-06-08ClinicalEffect of Metformin ER With Hypocaloric Diet on Weight Loss in Overweight/Obese Patients With Increased Waist CircumferenceResults expected Q4 2027
- 2026-06-02ClinicalEfficacy, Safety, and Pharmacokinetics of Tirzepatide Once Weekly Versus Placebo in Adolescent Participants Who Have Obesity, or Are Overweight With Weight-Related Comorbidities: A Randomized, Double-Blind Trial (SURMOUNT-ADOLESCENTS)Primary completion
- 2026-06-02ClinicalWeight Maintenance in Adolescents With Obesity; Long-Term Treatment With Semaglutide s.c.2.4 mg Once-weeklyResults expected Q4 2028
- 2026-06-01ClinicalEfficacy and Safety of Ixekizumab or Ixekizumab Concomitantly Administered With Tirzepatide in Adult Participants With Moderate-to-Severe Plaque Psoriasis and Obesity or Overweight: A Phase 3b, Randomized, Multicenter, Open-Label Study (TOGETHER-PsO)Completed
- 2026-05-29ClinicalA Master Protocol to Investigate the Efficacy and Safety of Orforglipron Once Daily in Participants With Hypertension and Obesity or Overweight: Randomized, Double-Blind, Placebo-Controlled Trials (ATTAIN-HYPERTENSION)Results expected Q3 2027
Clinical trials
The current development programme across all trial phases.
Clinical programme
24
6
18
6
Late-stage studies
Recently completed
Evidence coverage
How much of this condition's readable clinical evidence the confidence engine has incorporated, across its most-studied treatments. This measures coverage of the evidence base — not whether any treatment works.
Partial evidence coverage
Largest gap: off claim endpoint family (8, endpoint-family).
Research activity
Key research shaping understanding of this disease, combining the latest publications with the most influential evidence.
Publications over time
20192025
Major themes8
- Anti-Obesity Agents1
- Diet1
- Glucagon-Like Peptide 11
- Glucagon-Like Peptide-1 Receptor Agonists1
- Insulin Resistance1
- Obesity1
- Preconception Care1
- Pregnancy in Obesity1
Leading journals2
- Best practice & research. Clinical endocrinology & metabolism1
- Journal of diabetes research1
Leading researchers7
- Fuglsang J1
- Janež A1
- Jensterle M1
- Kampmann U1
- Knorr S1
- Koceva A1
- Ovesen P1
Affiliations (unnormalised)4
- Aarhus University Hospital1
- Steno Diabetes Center Aarhus1
- University Medical Center Ljubljana1
- University Medical Center Maribor1
Reference
Authoritative identity, definition & identifiers.
Defined in MeSH
BODY MASS INDEX in PREGNANT PEOPLE that is excessively above the recommended cut-off.
Identifiers
References & data sources
- Disease identity & definition — NLM Medical Subject Headings (MeSH), public domain
- Clinical trials — ClinicalTrials.gov (U.S. National Library of Medicine)
- Research activity — Europe PMC (EMBL-EBI) + OpenAlex-derived paper links
- Related entities are derived from literature co-mention (studied together) — associative, not causal.